Kite’s CAR T-Cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

0
284
Kite announced that the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus® for the treatment of adult patients 26 years of age and above with r/r ALL.
[Gilead Sciences, Inc.]
Press Release